Evidence map›Paper›PMID 25575541›Full record

Trial reportBlood2015

A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.

Hai Zhou, Miao Xu, Ping Qin, Hai-yan Zhang, Cheng-lu Yuan, Hong-guo Zhao, Zhong-guang Cui, Yue-sheng Meng, Lei Wang, Fang Zhou and 12 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01525836 (Recombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP.), which is not on this map. Cited by 57 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 8 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01525836 phase3completednot on this map

Recombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP.

TypeinterventionalSponsorShandong UniversityRan2011 to 2014Enrolled123ConditionsPurpura, Idiopathic Thrombocytopenic PurpuraArmsrituximab, recombinant human thrombopoietin (rhTPO), Rituximab
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 8 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy.Hematology. American Society of Hematology. Education Program · 2024
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 1 country.

Hai ZhouDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, China;
Miao XuDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, China;
Ping QinDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, China;
Hai-yan ZhangDepartment of Hematology, Linyi People's Hospital, Linyi, China;
Cheng-lu YuanDepartment of Hematology, Qingdao Central Hospital, Qingdao, China;
Hong-guo ZhaoDepartment of Hematology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, China;
Zhong-guang CuiDepartment of Hematology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, China;
Yue-sheng MengDepartment of Hematology, Qingdao Municipal Hospital, Qingdao, China;
Lei WangDepartment of Hematology, Qingdao Municipal Hospital, Qingdao, China;
Fang ZhouDepartment of Hematology, The General Hospital of Jinan Military Commanding Region, Jinan, China;
Xin WangDepartment of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, China;
Da-qi LiDepartment of Hematology, Shandong University Affiliated Jinan Center Hospital, Jinan, China;
Ke-hong BiDepartment of Hematology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, China;
Chuan-sheng ZhuDepartment of Hematology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, China;
Cheng-shan GuoDepartment of Hematology, Second Hospital of Shandong University, Jinan, China;
Xiao-xia ChuDepartment of Hematology, Yantai Yuhuangding Hospital, Yantai, China;
Qing-chao WuDepartment of Hematology, Qingdao Haici Hospital, Qingdao, China; and.
Xin-guang LiuDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, China;
Xiao-yuan DongDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, China;
Jie LiDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, China;
Jun PengDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, China; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Shandong University, Jinan, China.
Ming HouDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, China; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Shandong University, Jinan, China.
Qilu Hospital of Shandong University · CNQingdao University · CNShandong University · CNGeneral Hospital of Jinan Military Command · CNJinan Central Hospital · CNLinyi People's Hospital · CNSecond Hospital of Shandong University · CNShandong Provincial Hospital · CNShandong Provincial QianFoShan Hospital · CNTianjin haihe hospital · CNYuhuangding Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to compare the efficacy and safety of rituximab (RTX) plus recombinant human thrombopoietin (rhTPO) with RTX alone in patients with immune thrombocytopenia (ITP) who had failed to respond to corticosteroids or relapsed. Recruited patients were randomized at a ratio of 2:1 into 2 groups: the combination group (RTX + rhTPO, n = 77) and the monotherapy group (RTX, n = 38). Overall response was achieved in 79.2% of patients in the combination group vs 71.1% in the monotherapy group (P = .36), and the complete response (CR) rate was 45.4% in the combination group compared with 23.7% in the monotherapy group (P = .026). The combination group had significantly shorter time to response (TTR; median and range, 7 and 4-28 days) compared with the monotherapy group (28 and 4-90 days) (P < .01). There was no difference between these 2 groups in terms of the long-term response (P = .12). Our findings demonstrated that the combination of RTX and rhTPO significantly increased the CR rate and shortened TTR compared with RTX monotherapy in the treatment of corticosteroid-resistant or relapsed ITP but failed to show a beneficial effect on the long-lasting response. This study is registered at www.clinicaltrials.gov as #NCT01525836.

Indexed as

AdolescentAdrenal Cortex HormonesAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAutoantibodiesChildCombined Modality TherapyDrug ResistanceFemaleHumansMaleMiddle AgedPlatelet CountPurpura, Thrombocytopenic, IdiopathicAdrenal Cortex HormonesAntibodies, Monoclonal, Murine-DerivedAutoantibodiesRecombinant ProteinsRituximabThrombopoietin

Identifiers

PMID25575541
PMCPMC4351949
OpenAlexW2057719284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.